Oncobiologics (OTLK) Competitors $1.58 -0.02 (-1.25%) Closing price 07/1/2025 04:00 PM EasternExtended Trading$1.63 +0.05 (+3.23%) As of 06:46 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OTLK vs. IMMP, DSGN, CMPS, ACB, BTMD, CGC, YMAB, TVGN, INBX, and CRDFShould you be buying Oncobiologics stock or one of its competitors? The main competitors of Oncobiologics include Prima BioMed (IMMP), Design Therapeutics (DSGN), COMPASS Pathways (CMPS), Aurora Cannabis (ACB), biote (BTMD), Canopy Growth (CGC), Y-mAbs Therapeutics (YMAB), Semper Paratus Acquisition (TVGN), Inhibrx Biosciences (INBX), and Cardiff Oncology (CRDF). These companies are all part of the "pharmaceutical products" industry. Oncobiologics vs. Its Competitors Prima BioMed Design Therapeutics COMPASS Pathways Aurora Cannabis biote Canopy Growth Y-mAbs Therapeutics Semper Paratus Acquisition Inhibrx Biosciences Cardiff Oncology Prima BioMed (NASDAQ:IMMP) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations and valuation. Is IMMP or OTLK more profitable? Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Oncobiologics N/A N/A -271.12% Which has better earnings & valuation, IMMP or OTLK? Prima BioMed has higher revenue and earnings than Oncobiologics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$5.14M46.88-$28.01MN/AN/AOncobiologicsN/AN/A-$75.37M-$0.91-1.74 Which has more volatility & risk, IMMP or OTLK? Prima BioMed has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Oncobiologics has a beta of 0.26, suggesting that its share price is 74% less volatile than the S&P 500. Does the media prefer IMMP or OTLK? In the previous week, Oncobiologics had 1 more articles in the media than Prima BioMed. MarketBeat recorded 2 mentions for Oncobiologics and 1 mentions for Prima BioMed. Prima BioMed's average media sentiment score of 1.87 beat Oncobiologics' score of 0.94 indicating that Prima BioMed is being referred to more favorably in the media. Company Overall Sentiment Prima BioMed Very Positive Oncobiologics Positive Do institutionals & insiders believe in IMMP or OTLK? 2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 11.2% of Oncobiologics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 4.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Do analysts recommend IMMP or OTLK? Prima BioMed currently has a consensus target price of $7.00, indicating a potential upside of 324.24%. Oncobiologics has a consensus target price of $9.60, indicating a potential upside of 507.59%. Given Oncobiologics' higher possible upside, analysts clearly believe Oncobiologics is more favorable than Prima BioMed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Oncobiologics 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 SummaryPrima BioMed beats Oncobiologics on 6 of the 11 factors compared between the two stocks. Get Oncobiologics News Delivered to You Automatically Sign up to receive the latest news and ratings for OTLK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OTLK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OTLK vs. The Competition Export to ExcelMetricOncobiologicsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$53.71M$2.85B$5.48B$8.94BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-1.7421.1726.2119.74Price / SalesN/A262.85395.44109.12Price / CashN/A41.8936.4957.06Price / Book-0.517.237.935.37Net Income-$75.37M-$55.05M$3.15B$248.34M7 Day Performance-12.22%-0.60%0.75%1.67%1 Month Performance-10.73%3.77%3.45%4.56%1 Year Performance-77.72%2.20%34.85%18.42% Oncobiologics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OTLKOncobiologics2.079 of 5 stars$1.58-1.3%$9.60+507.6%-78.7%$53.71MN/A-1.7420IMMPPrima BioMed1.4444 of 5 stars$1.52-5.0%$7.00+360.5%-17.9%$221.98M$5.14M0.002,021Gap UpDSGNDesign Therapeutics1.3933 of 5 stars$3.90+4.3%$4.00+2.6%+8.3%$221.40MN/A-3.9440Positive NewsCMPSCOMPASS Pathways2.089 of 5 stars$2.35-49.2%$17.00+623.4%-46.9%$219.87MN/A-1.18120High Trading VolumeACBAurora Cannabis0.2978 of 5 stars$3.91-4.2%N/A-7.3%$219.78M$246.72M35.551,073BTMDbiote3.3746 of 5 stars$4.01+1.3%$8.00+99.5%-44.3%$219.39M$197.19M6.57194CGCCanopy Growth2.5918 of 5 stars$1.19-4.0%$2.00+68.1%-82.3%$218.80M$269.00M-0.293,150YMABY-mAbs Therapeutics2.9319 of 5 stars$4.72+7.0%$15.60+230.5%-62.7%$213.74M$88.66M-7.38150TVGNSemper Paratus Acquisition4.1355 of 5 stars$1.16-3.3%$7.10+512.1%+66.7%$213.32MN/A0.003INBXInhibrx Biosciences1.5278 of 5 stars$14.56-2.5%N/A+6.8%$210.77M$200K0.12166CRDFCardiff Oncology1.6549 of 5 stars$3.16+1.9%$12.00+279.7%+71.2%$210.22M$587K-3.4320 Related Companies and Tools Related Companies Prima BioMed Competitors Design Therapeutics Competitors COMPASS Pathways Competitors Aurora Cannabis Competitors biote Competitors Canopy Growth Competitors Y-mAbs Therapeutics Competitors Semper Paratus Acquisition Competitors Inhibrx Biosciences Competitors Cardiff Oncology Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OTLK) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncobiologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncobiologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
